Luveltamab tazevibulin clinical trials
Also written STRO-002.
How each study uses luveltamab tazevibulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Sutro Biopharma, Inc. (5) · Tasly Pharmaceutical Group Co., Ltd (1)
Studies
Open first, then newest update. How each study uses luveltamab tazevibulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLTerminatedPhase 1/2Sutro Biopharma, Inc.NCT06679582Written as Luveltamab tazevibulinHow we know
- A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid TumorsCompletedPhase 1/2Tasly Pharmaceutical Group Co., LtdNCT06238687Written as STRO-002How we know
- REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1TerminatedPhase 2/3Sutro Biopharma, Inc.NCT05870748Written as Luveltamab tazevibulinHow we know
- A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerTerminatedPhase 1Sutro Biopharma, Inc.NCT05200364Written as STRO-002How we know
- Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerWithdrawnPhase 2Sutro Biopharma, Inc.NCT06555263Written as Luveltamab tazevibulinHow we know
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersCompletedPhase 1Sutro Biopharma, Inc.NCT03748186Written as STRO-002How we know
Codes
What other systems call luveltamab tazevibulin · ClinicalTrials.gg INT018458
- UNII (FDA) XDE2GOF1JTLUVELTAMAB TAZEVIBULINOne source FDA
- NCI Thesaurus C158067Luveltamab TazevibulinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XDE2GOF1JT | LUVELTAMAB TAZEVIBULIN | One source FDA |
| NCI Thesaurus | C158067 | Luveltamab Tazevibulin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.